Improvement in Palivizumab Administration in Severely Immunocompromised Children: A Single-institution Quality Improvement Initiative
We improved adherence to palivizumab administration guidelines for profoundly immunocompromised children over 8 consecutive RSV seasons without increasing RSV infection incidence or severity.
Authors
- Randall T. Hayden (ORCID: https://orcid.org/0000-0002-3073-4115)
- Ronald H. Dallas (ORCID: https://orcid.org/0000-0002-3259-6801)
- Jose Ferrolino (ORCID: https://orcid.org/0000-0003-4008-5507)
- William L. Greene (ORCID: https://orcid.org/0000-0001-5437-9798)
- Octavio Ramilo (ORCID: https://orcid.org/0000-0002-0565-5239)
- Diego R. Hijano (ORCID: https://orcid.org/0000-0002-2903-666X)
- Shane J. Cross (ORCID: https://orcid.org/0000-0001-7287-6851)
- Jonathan D. Burlison (ORCID: https://orcid.org/0000-0003-2315-5067)
- Ted Morton (ORCID: https://orcid.org/0009-0008-3590-2086)
- Hailey S Ross (ORCID: https://orcid.org/0009-0002-1169-8670)
- Patricia M. Flynn (ORCID: https://orcid.org/0000-0002-9828-6160)
- Joshua Wolf (ORCID: https://orcid.org/0000-0002-9912-3646)
- Delia C Allen
Institutions
- St. Jude Children's Research Hospital (US)
- University of Tennessee Health Science Center (US)
Publication Details
- Journal
- Pediatric Quality and Safety
- Published
- 2025-06-19
- DOI
- https://doi.org/10.1097/pq9.0000000000000822
- Primary Topic
- Respiratory viral infections research
- Type
- article
- Field-Weighted Citation Impact
- 0.00